A case of clinical and microbiological failure of azithromycin therapy in Salmonella enterica serotype Typhi despite low azithromycin MIC

Int J Infect Dis. 2017 Jan:54:62-63. doi: 10.1016/j.ijid.2016.11.409. Epub 2016 Nov 25.

Abstract

Typhoid fever remains a serious problem in many developing countries. Due to resistance to multiple first line drugs, azithromycin has evolved as an important drug in the treatment of typhoid. While therapy with azithromycin is highly effective, no clinically validated mean inhibitory concentration (MIC) break points or disc diffusion cutoff guidelines are available so far. We describe an Indian adult with clinical and microbiological failure to azithromycin despite low azithromycin MIC.

Keywords: Azithromycin; MIC within susceptible range; Salmonella enterica serotype Typhi; clinical failure.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / pharmacology
  • Azithromycin / therapeutic use*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Salmonella typhi / drug effects*
  • Salmonella typhi / isolation & purification
  • Salmonella typhi / physiology
  • Serogroup
  • Treatment Failure
  • Typhoid Fever / drug therapy*
  • Typhoid Fever / microbiology
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Azithromycin